6. of Barnet, M.B., et al., Australian study into the impact of Sep 2016 diagnostic Advanced (double or multiple mutation), accuracy NSCLC and Response to compared with a single mutation, of the EGFR Tyrosine Kinase EGFR gene on response to tyrosine kinase Inhibitors. J Thorac Oncol, inhibitors (TKIs) in patients with online Sep 2016 ahead of metastatic non small cell lung cancer publication, (NSCLC). The study included 62 patients; eight (12.9%) with a co-mutation. Progression-free survival (PFS) in patients with EGFR co-mutation was shorter, and response rate significantly lower, than in patients with a single mutation. The study demonstrated that data from multipanel testing identifies subgroups of patients who are likely to respond poorly to standard treatment and clarification of these subgroups may improve patient care. 7. Clinical trial Hollebecque A, Massard C, Clinical of patients with advanced 2013 De Baere T, Auger N, solid tumours who had failed a standard Lacroix L, Koubi-Pick V, et therapy. Biopsies of the patients’ al. Molecular screening for metastatic cancers were sequenced for cancer treatment 30 target genes. PFS using therapy based optimization (MOSCATO on the genomic alterations (GA) was 01): A prospective compared to PFS on most recent therapy molecular triage [129 patients, 111 (86%) had tumor results. J Clin biopsy, 52 had an actionable target Oncol 2013; 31, (suppl; (40%); 25 pts (23% of biopsied pts) abstr 2512). treated with a targeted therapy]. The trial interim results demonstrate improved anti-tumour activity results for specific GA. 8. Cost-benefit Kircher SM, Mohindra N, US cost-benefit study of expanding RAS 2015 analysis Nimeiri H: Cost estimates testing for metastatic colorectal cancer. and economic implications The study concluded that the increased of expanded RAS testing societal cost of expanded RAS testing
6. of diagnostic accuracy Barnet, M.B., et al., Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol, online Sep 2016 ahead of publication, Australian study into the impact of (double or multiple mutation), compared with a single mutation, of the EGFR gene on response to tyrosine kinase inhibitors (TKIs) in patients with metastatic non small cell lung cancer (NSCLC). The study included 62 patients; eight (12.9%) with a co-mutation. Progression-free survival (PFS) in patients with EGFR co-mutation was shorter, and response rate significantly lower, than in patients with a single mutation. The study demonstrated that data from multipanel testing identifies subgroups of patients who are likely to respond poorly to standard treatment and clarification of these subgroups may improve patient care. Sep 2016 7. Clinical trial Hollebecque A, Massard C, De Baere T, Auger N, Lacroix L, Koubi-Pick V, et al. Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage results. J Clin Oncol 2013; 31, (suppl; abstr 2512). Clinical of patients with advanced solid tumours who had failed a standard therapy. Biopsies of the patients’ metastatic cancers were sequenced for 30 target genes. PFS using therapy based on the genomic alterations (GA) was compared to PFS on most recent therapy [129 patients, 111 (86%) had tumor biopsy, 52 had an actionable target (40%); 25 pts (23% of biopsied pts) treated with a targeted therapy]. The trial interim results demonstrate improved anti-tumour activity results for specific GA. 2013 8. Cost-benefit analysis Kircher SM, Mohindra N, Nimeiri H: Cost estimates and economic implications of expanded RAS testing US cost-benefit study of expanding RAS testing for metastatic colorectal cancer. The study concluded that the increased societal cost of expanded RAS testing 2015
Application-to-MSAC-RCPA-SomaticTumourGenePanel-Version%202.4(revised).docx